Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumors Cancer: early-phase trial registry
4 of 10 indexed Advanced Solid Tumors Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 4 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Advanced Solid Tumors Cancer: 10 US clinical trials tracked, 4 recruiting.
Advanced Solid Tumors Cancer is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 6 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumors-cancer
OPEN 4 | RECR 40% | LATE 0 | EARLY 9 | RANK #1724 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acute Myeloid Leukemia (AML) (40% recruiting · 30 trials)
Advanced Solid Tumors Cancer lists 4 open slots (40% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumors Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumors Cancer is recruiting below its size-band peers.
4 of 10 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Solid Tumors Cancer research.
AbbVie accounts for 6 of 10 trials (60%). 5 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumors Cancer enrolment sits around 134 participants.
Median target enrolment is 134 among the 10 trials that report a genuine target (sentinel values excluded). 5 of those (50%) plan for fewer than 100 participants.
-
Advanced Solid Tumors Cancer research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Elephas
NCT07327489
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Nimbus Wadjet
NCT06898450
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
ProteinQure
NCT07190469
ORB-021 In Patients With Advanced Solid Tumors
Orionis Biosciences
NCT06607939
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
AbbVie
NCT03821935
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
NCT02099058
A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
AbbVie
NCT02988960
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
AbbVie
NCT04721015
A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)
AbbVie
NCT03234712
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
AbbVie
NCT04196283
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumors Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumors Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumors Cancer page
10 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Advanced Solid Tumors Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AbbVie sponsors the most Advanced Solid Tumors Cancer trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumors Cancer condition card totals 10 registered trials; most-linked intervention ABBV-181; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.